Gossamer Bio (NASDAQ: GOSS): Unpacking Exceptional Financial Efficiency in Biotech

Font: Financial Modeling Prep  • Aug 17, 2026

• Gossamer Bio demonstrates remarkable financial efficiency, with an ROIC significantly outperforming its WACC.
• The company's ROIC to WACC ratio of 106.17 highlights its superior capital utilization compared to industry peers.
• While most competitors struggle with value destruction, Gossamer Bio stands out as a leader in value creation within the biotech sector.

Gossamer Bio, Inc. (NASDAQ: GOSS) is a leading clinical-stage biopharmaceutical company. It focuses on developing seralutinib to treat pulmonary hypertension. While many companies in this stage typically consume significant cash with no immediate returns, Gossamer Bio presents a very different financial picture compared to its competitors in the biotech industry.

A key metric to measure a company's financial efficiency is to compare its Return on Invested Capital (ROIC) to its Weighted Average Cost of Capital (WACC). ROIC demonstrates how much profit a company generates from its invested capital, while WACC represents the average cost the company pays to use that money from investors and lenders.

Gossamer Bio shows an exceptional ROIC of 697.21% against a WACC of 6.57%. This results in an ROIC to WACC ratio of 106.17. In simple terms, for every dollar of capital Gossamer Bio uses, it generates over 106 times its cost, showcasing incredibly efficient use of its financing and strong capital efficiency.

When compared to its industry peers, Gossamer Bio's performance in value creation is in a league of its own. The only other company with a positive return is Homology Medicines, Inc. (NASDAQ: FIXX), with an ROIC to WACC ratio of 3.80. While positive, this is far below the significant value creation demonstrated by Gossamer Bio.

In stark contrast, other biotech competitors are currently destroying value. Alector, Inc. (NASDAQ: ALEC), Stoke Therapeutics, Inc. (NASDAQ: STOK), and Harpoon Therapeutics, Inc. (NASDAQ: HARP) all exhibit negative ROIC to WACC ratios. Harpoon Therapeutics shows the most significant value destruction with a ratio of -27.46, indicating its investments cost much more than they generate.